Meta AnalysisID 6131
中成药治疗早期糖尿病肾病的比较疗效：随机对照试验网状Meta分析
CRD42021242884
This network meta-analysis (NMA) aims to evaluate the efficacy of seven types of CPMs, including Bailing Capsule (BLC), Huangkui Capsule (HKC), Jinshuibao (JSB), Uremic Clearance Granule (UCG), Tripterygium (TG), Compoun
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6131
- Evidence Id
- 14689
- Core Evidence Id
- 14689
- Source Meta Analysis Id
- 6111
- Herb2 Meta Analysis Id
- HBMA006111
- Crd Id
- CRD42021242884
- Title
- Comparative Efficacy of Chinese Patent Medicines for Early Diabetic Nephropathy: A Network Meta-Analysis of Randomized Controlled Trials
- Review Question
- This network meta-analysis (NMA) aims to evaluate the efficacy of seven types of CPMs, including Bailing Capsule (BLC), Huangkui Capsule (HKC), Jinshuibao (JSB), Uremic Clearance Granule (UCG), Tripterygium (TG), Compound Xueshuantong Capsule (CXC), Shenyan Kangfu Tablet (SYKFT), combined with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) treating early DN, in order to provide better guidance for clinical treatment.
- Study Type Included
- RCTs.
- Condition Being Studied
- Diabetic nephropathy (DN), one of the most common microvascular complications of diabetes mellitus (DM), has been a major worldwide public health concern, which is now the principal cause of chronic kidney disease leading to end-stage kidney disease worldwide. As a primary contributor to the excess risk of all-cause and cardiovascular death in diabetes, DKD is a major contributor to the progressively expanding global burden of diabetes-associated morbidity and mortality. Traditional Chinese medicine (TCM) has been considered as a pivotal complementary and alternative method for DN with unique advantages of being inexpensive and fewer side effects, which can improve the subjective initiative and treatment compliance of patients .
- Participant
- Studies of patients suffering from early DN according to the staging criteria of Mogensen were eligible. No limitation on gender, race, region, or age.
- Animal
- Human Disease Modelled
- Intervention
- The experimental group was administered one of the CPMs (BLC, HKC, JSB, UGG, TG, CXC, SYKFT) combined with ACEI/ARB.
- Comparator Control
- The control group was treated with ACEI/ARB alone.
- Main Outcome
- Urine albumin excretion ratio (UAER), 24-hour urinary total protein (24 h UTP), serum creatinine (Scr), blood urea nitrogen (BUN). Measures of effect Measures or effect：For the UAER, 24 h UTP, Scr, BUN, we use Mean difference to calculate.
- Outcome Measure
- Additional Outcome
- The safety parameter, such as adverse drug reactions (ADRs) or adverse drug events (ADEs). Measures of effect For ADRs or ADEs, we use the odds ratios to calculate.
- Study Method
- 网络荟萃分析, 系统评价
- Keyword
- China; Diabetes Mellitus; Diabetic Nephropathies; Humans; Network Meta-Analysis; Nonprescription Drugs; Randomized Controlled Trials as Topic
- Contact
- Jie Zhao [email protected]
- Organisational Affiliation
- Hunan University of Chinese Medicine
- Funding Source
- This study was financially supported by the National Natural Science Foundation of China (No. 81860838), the Postdoctoral Science Foundation of China (No. 2017M612987). Shi Wei’s Studio for the Heritage of Famous Traditional Chinese Medicine Practitioners (NO. 2017[11]).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-03-15
- Registration Date
- 2021-04-14
- Anticipated Start Date
- 2021-03-15
- Anticipated Completion Date
- 2021-04-18
- Title Cn
- 中成药治疗早期糖尿病肾病的比较疗效：随机对照试验网状Meta分析
- Title En
- Comparative Efficacy of Chinese Patent Medicines for Early Diabetic Nephropathy: A Network Meta-Analysis of Randomized Controlled Trials
- Bilingual Status
- complete